Prediabetes is a major risk factor for severe health conditions, including cardiovascular and kidney diseases, cancer, and dementia.

Current strategies to prevent the progression from prediabetes to diabetes include lifestyle programs, metformin, and acarbose, but the effectiveness of other interventions is less clear.

The randomized controlled trial aims to evaluate the efficacy and safety of sodium-glucose co-transporter 2 inhibitors in people with prediabetes, incorporating a gender-based analysis for personalized benefits and robust safety profiles.

The research aims to provide clinically relevant endpoints to translate findings into actionable prevention strategies, focusing on glycemic control, weight loss, and other metabolic parameters.

The findings from this study could significantly impact diabetes prevention strategies by introducing sodium-glucose co-transporter 2 inhibitors as a viable option for individuals with prediabetes.